Theravance Biopharma, Inc. Increase (Decrease) in Deferred Charges
Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Deferred Charges of -$4.31 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCharges · last filed 2021-02-26
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for the quarter ending 2018-12-31 was -$938.00K.
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for the quarter ending 2018-09-30 was -$368.00K, a 327.16% decline year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for the quarter ending 2018-06-30 was -$898.00K, a 500.89% decline year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for the quarter ending 2018-03-31 was -$2.10M, a 820.55% decline year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for fiscal 2018 was -$4.31M, a 1545.64% decline from fiscal 2017.
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for fiscal 2017 was $298.00K, a 52.85% decline from fiscal 2016.
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for fiscal 2016 was $632.00K, a 14.49% increase from fiscal 2015.
- Theravance Biopharma, Inc. increase (decrease) in deferred charges for fiscal 2015 was $552.00K.
| Period end | Increase (Decrease) in Deferred Charges 3 month | Increase (Decrease) in Deferred Charges 6 month | Increase (Decrease) in Deferred Charges 9 month | Increase (Decrease) in Deferred Charges 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$938.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$1.31M derived: sum of 2 quarters · filed 2021-02-26 | -$2.20M derived: sum of 3 quarters · filed 2021-02-26 | -$4.31M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$1.27M derived: sum of 2 quarters · filed 2019-11-08 | -$3.37M 10-Q · filed 2019-11-08 | -$3.75M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$898.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$3.00M 10-Q · filed 2019-08-05 | -$3.38M derived: sum of 3 quarters · filed 2020-02-27 | -$3.22M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$2.10M 10-Q · filed 2019-05-10 | -$2.48M derived: sum of 2 quarters · filed 2020-02-27 | -$2.32M derived: sum of 3 quarters · filed 2020-02-27 | -$2.10M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$218.00K derived: sum of 2 quarters · filed 2020-02-27 | $6.00K derived: sum of 3 quarters · filed 2020-02-27 | $298.00K 10-K · filed 2020-02-27 |
| 2017-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $386.00K derived: sum of 2 quarters · filed 2018-11-08 | $678.00K 10-Q · filed 2018-11-08 | $871.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $516.00K 10-Q · filed 2018-08-02 | $709.00K derived: sum of 3 quarters · filed 2019-02-28 | $919.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $292.00K 10-Q · filed 2018-05-09 | $485.00K derived: sum of 2 quarters · filed 2019-02-28 | $695.00K derived: sum of 3 quarters · filed 2019-02-28 | $775.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $403.00K derived: sum of 2 quarters · filed 2019-02-28 | $483.00K derived: sum of 3 quarters · filed 2019-02-28 | $632.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $290.00K derived: sum of 2 quarters · filed 2017-11-08 | $439.00K 10-Q · filed 2017-11-08 | $587.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $229.00K 10-Q · filed 2017-08-09 | $377.00K derived: sum of 3 quarters · filed 2018-02-28 | $526.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $149.00K 10-Q · filed 2017-05-10 | $297.00K derived: sum of 2 quarters · filed 2018-02-28 | $446.00K derived: sum of 3 quarters · filed 2018-02-28 | $595.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $297.00K derived: sum of 2 quarters · filed 2018-02-28 | $446.00K derived: sum of 3 quarters · filed 2018-02-28 | $552.00K 10-K · filed 2018-02-28 |
| 2015-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $298.00K derived: sum of 2 quarters · filed 2016-11-09 | $404.00K 10-Q · filed 2016-11-09 | $324.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $149.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $255.00K 10-Q · filed 2016-08-09 | $175.00K derived: sum of 3 quarters · filed 2017-03-01 | $94.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $106.00K 10-Q · filed 2016-05-10 | $26.00K derived: sum of 2 quarters · filed 2017-03-01 | -$55.00K derived: sum of 3 quarters · filed 2017-03-01 | -$153.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$161.00K derived: sum of 2 quarters · filed 2017-03-01 | -$259.00K derived: sum of 3 quarters · filed 2017-03-01 | -$376.00K 10-K · filed 2017-03-01 |
| 2014-09-30 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$179.00K derived: sum of 2 quarters · filed 2015-11-12 | -$296.00K 10-Q · filed 2015-11-12 | -$412.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | -$98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$215.00K 10-Q · filed 2015-08-13 | -$331.00K derived: sum of 3 quarters · filed 2016-03-11 | -$291.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | -$117.00K 10-Q · filed 2015-05-13 | -$233.00K derived: sum of 2 quarters · filed 2016-03-11 | -$193.00K derived: sum of 3 quarters · filed 2016-03-11 | -$19.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | -$116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$76.00K derived: sum of 2 quarters · filed 2016-03-11 | $98.00K derived: sum of 3 quarters · filed 2016-03-11 | $300.00K 10-K · filed 2016-03-11 |
| 2013-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $214.00K derived: sum of 2 quarters · filed 2014-11-12 | $416.00K 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $376.00K 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $202.00K 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | $747.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |